AWARD
66 -- CisBio Bioassays Reagents
- Notice Date
- 2/9/2012
- Notice Type
- Award Notice
- NAICS
- 333999
— All Other Miscellaneous General Purpose Machinery Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHGRI-CSB-(HG)-2012-050-RSF
- Archive Date
- 2/17/2012
- Point of Contact
- Rashida S. Ferebee, Phone: 3014352605
- E-Mail Address
-
ferebeers@nhlbi.nih.gov
(ferebeers@nhlbi.nih.gov)
- Small Business Set-Aside
- N/A
- Award Number
- HHSN268201200048P
- Award Date
- 2/2/2012
- Awardee
- Cisbio US Inc., 135 South Road, Bedford, Massachusetts 01730, United States
- Award Amount
- $43, 800.75
- Description
- The sole source determination is based upon the fact that Cisbio Bioassays US does not distribute this item to any other resellers; as such, Cisbio Bioassays US is the sole provider of this particular reagent. Additionally, the pSer473 AKT HTRF® Cisbio assay consists of reagents labeled proprietary fluorophores. Akt is an important kinase enzyme involved in cell growth, survival, proliferation and differentiation. Phosphorylation of AKT at the amino acid Ser473 is a critical regulatory step of AKT activity. NCGC has done extensive work to miniaturize the assay to 1536-well format and demonstrated that it produces robust data using the HTS capabilities at NCGC by doing pilot screens with small compound collections. The current HTRF® Cisbio assay is ready for HTS at NCGC. At this moment, there is no alternative assay available to measure pSer473 AKT that would allow NCGC to screen of a large collection of compounds (400,000). NCGC must use the same variables in the assays to maintain integrity from the data and to achieve the desired outcomes. This item has been purchased in the past from this vendor only, as no one else can provide these specific reagents. All the assay optimization was performed with the HTRF® kits. Going forward, the screening needs to be done with the same reagents in order to yield comparable and readily interpretable results. A switch to a different detection reagent would necessitate re-optimizing the assay with no guarantees that the results would be similar. This would entail unacceptable substantial time delays and enormous additional costs.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/Awards/HHSN268201200048P.html)
- Record
- SN02672271-W 20120211/120210114612-4333d1574df53684f900d5c880418c42 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |